Teligent Closes $25 Million Secured Credit Facility

6/5/18

BUENA, N.J., June 05, 2018 (GLOBE NEWSWIRE) -- TELIGENT, Inc. (NASDAQ:TLGT) Teligent, Inc. announced today that it has entered into a Credit Agreement with certain funds managed by Highbridge Capital Management, LLC, an existing stakeholder, on June 1, 2018. Pursuant to the Credit Agreement, the lenders provided Teligent with a new senior-secured term loan credit facility in the principal amount of $25 million with a maturity date of June 1, 2021. Teligent drew $15 million of the facility on the closing date, with the remaining $10 million available within 45 days of the closing date subject to the satisfaction of certain post-closing conditions. In addition to the $25 million principal amount, the Credit Agreement provides that an incremental facility of up to an additional $50 million may be made available to Teligent up until September 15, 2018, subject to the discretion of the lenders and the other terms of the Credit Agreement. The funds will be used by Teligent to pursue certain product launches as well as address its capital structure.

“Teligent has won a number of key approvals recently and the proceeds of this Credit Agreement will provide Teligent with the necessary working capital to fund the product launches related to these approvals while also putting Teligent in a position to improve its capital structure,” commented Jason Grenfell-Gardner, Teligent’s President and CEO. “That this facility was provided by existing stakeholders is a testament to their belief in our business and strategy.”

About Teligent, Inc.

Teligent is a specialty generic pharmaceutical company. Teligent’s mission is to be a leading player in the specialty generic prescription drug market. Under its own label, Teligent currently markets and sells generic topical and branded generic and generic injectable pharmaceutical products in the United States and Canada.